These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36315443)

  • 21. Are Patients With
    Palermo S; Giovannelli F; Bartoli M; Amanzio M
    Front Pharmacol; 2019; 10():502. PubMed ID: 31156432
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Yang XH; Cai DB; Ungvari GS; Ng CH; Wang SB; Wang YY; Ning YP; Xiang YT
    Psychol Med; 2018 Jan; 48(1):72-81. PubMed ID: 28528597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder: A Meta-Analysis and Comparison of Meta-Regression and MetaForest.
    Castells X; Saez M; Barcheni M; Cunill R; Serrano D; López B; van Lissa CJ
    Int J Neuropsychopharmacol; 2022 Jan; 25(1):26-35. PubMed ID: 34355753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials.
    Kishi T; Oya K; Matsui Y; Nomura I; Sakuma K; Okuya M; Matsuda Y; Fujita K; Funahashi T; Yoshimura R; Iwata N
    Neuropsychiatr Dis Treat; 2018; 14():2519-2530. PubMed ID: 30319261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
    Levine SZ; Leucht S
    Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data.
    Matsusaki A; Kaneko M; Narukawa M
    Clin Drug Investig; 2018 Aug; 38(8):751-761. PubMed ID: 29858840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
    Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
    Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies.
    Storosum BWC; Mattila T; Wohlfarth TD; Gispen-de Wied CC; Roes KCB; den Brink WV; de Haan L; Denys DAJP; Zantvoord JB
    Psychiatry Res; 2023 Feb; 320():114997. PubMed ID: 36603382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
    Kishi T; Matsuda Y; Iwata N
    Psychopharmacology (Berl); 2017 Jul; 234(14):2113-2125. PubMed ID: 28508107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological approaches to treating negative symptoms: a review of clinical trials.
    Arango C; Garibaldi G; Marder SR
    Schizophr Res; 2013 Nov; 150(2-3):346-52. PubMed ID: 23938176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of 5-HT2A antagonists on negative symptoms in patients with schizophrenia: A meta-analysis.
    Romeo B; Willaime L; Rari E; Benyamina A; Martelli C
    Psychiatry Res; 2023 Mar; 321():115104. PubMed ID: 36774749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventions for smoking cessation and reduction in individuals with schizophrenia.
    Tsoi DT; Porwal M; Webster AC
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD007253. PubMed ID: 23450574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia - A systematic review and meta-analysis.
    Seppälä A; Pylvänäinen J; Lehtiniemi H; Hirvonen N; Corripio I; Koponen H; Seppälä J; Ahmed A; Isohanni M; Miettunen J; Jääskeläinen E
    Schizophr Res; 2021 Oct; 236():123-134. PubMed ID: 34496316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials.
    Jin Y; Wang Q; Wang Y; Liu M; Sun A; Geng Z; Lin Y; Li X
    Shanghai Arch Psychiatry; 2017 Aug; 29(4):191-199. PubMed ID: 28955138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
    Haddad PM; Correll CU
    Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.
    Kishi T; Nosaka T; Sakuma K; Okuya M; Iwata N
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):314-322. PubMed ID: 32767739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
    Huhn M; Nikolakopoulou A; Schneider-Thoma J; Krause M; Samara M; Peter N; Arndt T; Bäckers L; Rothe P; Cipriani A; Davis J; Salanti G; Leucht S
    Lancet; 2019 Sep; 394(10202):939-951. PubMed ID: 31303314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence.
    Ulrich S; Messer T
    Curr Med Res Opin; 2021 Jul; 37(7):1233-1248. PubMed ID: 33651656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modafinil for people with schizophrenia or related disorders.
    Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Iwata N
    J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.